A B S T R A C T Synthetic thyrotropin-releasing hormone (TRH) was administered to normal children and hypopituitary patients in a dose of 7 jg/kg i.v. over 30-60 sec. Serum thyrotropin (TSH) and prolactin (HPr) concentrations were measured by radioimmunoassay before and at 15-min intervals for 2 hr after TRH. In 20 normal children HPr rose from a mean baseline value of 7.0±1.2 (SEM) ng/ml to a mean peak value of 39.5±5 ng/ml.
INTRODUCTION
Thyrotropin-releasing hormone (TRH)1 releases thyrotropin (TSH) in vivo from the pituitaries of normal adults (1-10) and children (11, 12) , and most patients with idiopathic hypopituitarism (11) (12) . We have reported (11) that 13 of 13 children with growth hormone (GH) deficiency without apparent TSH deficiency, 10 of 13 children with idiopathic GH deficiency plus TSH deficiency, and 1 of 5 children with GH and TSH deficiency secondary to operative procedures for craniopharyngiomas released TSH to a comparable extent as normal children after TRH injection. The interpretation of these data by our group (11) and similar data by Costom, Grumbach, and Kaplan (12) was that at least some children with apparent TSH deficiency had idiopathic hypopituitarism because an apparently normal pituitary gland was not receiving the appropriate releasing stimulus for TSH.
Subsequent to the demonstration that TRH releases TSH from the pituitary, TRH has also been shown to elevate prolactin levels from cloned rat pituitary tumor cells in vitro (13) and in normal subjects (14) (15) . The current study was undertaken to evaluate the release of prolactin (HPr) secondary to TRH stimulation in normal children and in the hypopituitary patients referred to above.
METHODS
Unless otherwise designated in the tables, 7 /Ag of TRH per kg of body weight were given i.v. over a 30-60 sec period. Serum samples were collected at -20, 0, 15, 30, 45, and 60 min, and in most patients at 90 and 120 min. TSH, serum thyroxine, free thyroxine (T4) (16) , and GH concentrations (17) , and serum HPr concentrations (18, 19) were measured as previously reported. No cross-reaction between TSH, HPr, or GH could be demonstrated in the assay systems.
The majority of normal children were siblings of patients seen in our endocrine clinic and were prepubertal. One patient was seen for intrauterine growth retardation and two Table I , and the group response is compared with that of other groups in Fig. 1 . Fasting levels of HPr ranged from < 2.3 ng/ml to a maximum of 23.0 ng/ml. The majority of fasting HPr levels were less than 10 ng/ml and the average of the means at -20 and 0 min was 7.0±1.2 ng/ml (SEM). The average of the mean TSH levels at these times was 2.2±0.3 /U/ml. By (Table II) . As previously reported (11) and as demonstrated in Fig. 1 Table III are obviously different than the others in respect to HPr, the data of these three were not used to calculate the mean values at each time for reasons cited above for patient S. C.
The mean HPr levels for -20 and 0 min (25.0±5.0 ng/ml) were significantly higher (P < 0.005) than the mean baseline levels for normal children (7.1±1.2 ng/ ml). Similarly the peak responses of HPr (65.8±10.0 ng/ml) were significantly higher (P < 0.025) than those of normal children (39.5±5.0 ng/ml) as were the peak responses of TSH (P < 0.05).
Of the 14 patients in group III, nine had repeat TRH tests with the same amount of TRH after they had received replacement thyroid therapy for several months (Table III-B) . In eight, the previously elevated mean baseline HPr levels were significantly lower (P < 0.001) after thyroid replacement therapy (7.6±+1.0 ng/ml), and were the same as group I. In addition, the peak HPr levels were significantly less (P < 0.01) after thyroid replacement therapy (23.3±4.6 ng/ml) when compared with the levels while receiving no thyroid therapy. In the one remaining patient in group (15, 20) , and is probably secondary to the differences in circulating estrogen levels (15) . This speculation would support our finding of no male-female differences in prepubertal children. (21) . ' 
